Interim miss slows IO Biotech
An accelerated approval looks off the table, as the group’s first-line melanoma trial continues.
The month ahead: September’s upcoming events
It’s back to school for biotech, with a packed conference schedule.
ESMO 2024 preview – presidential focus
Second time lucky for Zynyz, Amgen’s PRMT5 comeback, and other possible surprises.
ESMO 2024 preview – TIGIT gets its late-breaker
Belrestotug’s lung cancer trial features among the ESMO late-breakers, as do Immutep, Scorpion and others.
TIGIT blows up in a trial that always looked risky
Keyvibe-008 is halted for futility, an outcome that might have been foreseen in 2022.
